Monte Rosa Therapeutics, Inc.GLUENASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank33
3Y CAGR-30.5%
5Y CAGR-40.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-30.5%/yr
Annual compound
5Y CAGR
-40.5%/yr
Recent acceleration
Percentile
P33
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthDecelerating
| Period | Value |
|---|---|
| 2025 | 16.40% |
| 2024 | 15.72% |
| 2023 | 23.50% |
| 2022 | 48.83% |
| 2021 | 143.54% |
| 2020 | 219.29% |
| 2019 | 0.00% |